论文部分内容阅读
目的对醒脑静联合依达拉奉治疗重症脑梗死的临床疗效展开研究。方法 80例重症脑梗死患者作为研究对象,按随机数字表法分成探究组与对照组,各40例。对照组患者采用单一的醒脑静进行治疗,探究组患者在采用醒脑静治疗的同时联合依达拉奉进行治疗。对比两组患者的临床治疗效果。结果探究组患者治疗总有效率95.00%高于对照组67.50%,差异具有统计学意义(P<0.05)。治疗前,两组患者的神经功能缺损评分及生活能力评分对比,差异均无统计学意义(P>0.05);治疗后,两组患者的神经功能缺损评分及生活能力评分均较本组治疗前改善,且探究组改善程度优于对照组,差异均具有统计学意义(P<0.05)。结论针对重症脑梗死患者给予醒脑静联合依达拉奉进行治疗能有效改善患者病情症状,降低安全风险,疗效可靠。
Objective To study the clinical effect of Xingnaojing combined with edaravone in the treatment of severe cerebral infarction. Methods Eighty patients with severe cerebral infarction were divided into study group and control group according to random number table method, 40 cases in each group. Patients in the control group were treated with a single xingnaojing, while patients in the study group were treated with edaravone while xingjing was treated. The clinical effects of two groups were compared. Results The total effective rate of treatment group was 95.00% higher than 67.50% of control group, the difference was statistically significant (P <0.05). Before treatment, there was no significant difference between the two groups in neurological deficit score and life ability score (P> 0.05). After treatment, the score of neurological deficit and life ability score of the two groups were significantly higher than those before treatment Improve, and improve the degree of exploration group better than the control group, the difference was statistically significant (P <0.05). Conclusions The treatment of patients with severe cerebral infarction with xingnaojing combined with edaravone can effectively improve the patients’ symptoms and reduce the safety risk, and the curative effect is reliable.